Sanofi - ADR (SNY): Price and Financial Metrics
Sanofi - ADR (SNY)
Today's Latest Price: $48.68 USD
Updated May 28 6:55pm
Add SNY to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 214 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
SNY Stock Summary
- SNY has a higher market value than 98.7% of US stocks; more precisely, its current market capitalization is $122,072,560,697.
- With a price/earnings ratio of 40.02, Sanofi P/E ratio is greater than that of about 81.1% of stocks in our set with positive earnings.
- The volatility of Sanofi's share price is greater than that of merely 1.24% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to Sanofi are GSK, AMGN, MDT, BMY, and DHR.
- Visit SNY's SEC page to see the company's official filings. To visit the company's web site, go to www.sanofi.com.
SNY Stock Price Chart More Charts
SNY Price/Volume Stats
| Current price | $48.68 | 52-week high | $51.84 |
| Prev. close | $47.49 | 52-week low | $37.62 |
| Day low | $47.96 | Volume | 1,763,500 |
| Day high | $49.12 | Avg. volume | 2,330,334 |
| 50-day MA | $46.13 | Dividend yield | 2.4% |
| 200-day MA | $46.76 | Market Cap | 121.90B |
Sanofi - ADR (SNY) Company Bio
Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The company operates in three segments: Pharmaceuticals, Vaccines, and Animal Health. The company was founded in 1973 and is based in Paris, France.
SNY Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $48.68 | $68.95 | 45% |
Below please find a table outlining a discounted cash flow forecast for SNY, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Sanofi ranked in the 57th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. The most interesting components of our discounted cash flow analysis for Sanofi ended up being:
- In the past 4.99 years, Sanofi has a compound free cash flow growth rate of 0.02%; that's higher than merely 23.81% of free cash flow generating stocks in the Healthcare sector.
- Sanofi's weighted average cost of capital (WACC) is 7%; for context, that number is higher than just 12.16% of tickers in our DCF set.
- SNY's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than just 12.16% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 42% |
| 1% | 44% |
| 2% | 45% |
| 3% | 47% |
| 4% | 48% |
| 5% | 49% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as SNY, try DRRX, UHS, PBH, AHPI, and MEDP.
Loading social stream, please wait...